Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume 22, Issue 3, Pages 585-587Publisher
WILEY
DOI: 10.1111/ene.12487
Keywords
disease modifying drugs; disease reactivation; fingolimod; multiple sclerosis; natalizumab; treatment interruption
Categories
Ask authors/readers for more resources
Background and purposeNatalizumab discontinuation induces the recurrence of multiple sclerosis disease activity: currently no therapeutic approach has been found able to abolish disease reactivation. MethodsThe recurrence of disease activity after natalizumab discontinuation was retrospectively evaluated in 79 patients who had been treated with immunomodulating agents, other first-line therapies, fingolimod or not treated. ResultsNo differences have been found in clinical or magnetic resonance imaging recurrence of disease activity amongst the groups. Interestingly, no disease reactivation was observed only in one patient treated for 6months with monthly pulses of cyclophosphamide. ConclusionDisease modifying treatment or no treatment' is unable to abolish disease activity reactivation after natalizumab discontinuation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available